Corning Jerry Pharmaceutical-B (09966) announced its 2023 annual results, with revenue of RMB 219 million, an increase over the previous year...
According to the Zhitong Finance App, Corning Jerry Pharmaceutical-B (09966) announced its 2023 results, with revenue of RMB 219 million, up 31.12% year on year; loss was RMB 211 million during the year, and losses narrowed 35.35% year on year; basic loss per share was RMB 0.22.
For the year ended 31 December 2023, the Group recorded drug sales and royalty revenue of RMB 195.6 million, compared with RMB 147.5 million for the year ended 31 December 2022, mainly from Sichuan Silu Kangrui Pharmaceutical Co., Ltd. (“Sichuan Silu Kangrui Pharmaceutical”). The Group and Siludi Pharmaceuticals signed a license agreement for the joint development and commercialization of KN035 in February 2016. Revenue from sales of KN035 products to Sichuan Silu Kangrui Pharmaceutical for the year ended December 31, 2023 was RMB 128.4 million (2022: RMB 86.0 million). The Group recognizes this revenue upon delivery of the goods and the transfer of control over the goods.